Skip to main content

Table 1 Demographic and clinical characteristics of patients

From: Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study

Demographic and clinical characteristic No. of patients
(n = 85)
Age, year
 Mean (+ SD) 59.1 + 10.8
Gender, No. (%)
 Female 47 (55.3)
 Male 38 (44.7)
Ethnicity, No. (%)
 Chinese 63 (74.1)
 Non-Chinese (Malay and Indian) 22 (25.9)
Smoking history, No. (%)
 Never smoker 67 (78.8)
 Previous or current smoker 18 (21.2)
ECOG performance status at diagnosis, No. (%)
 ECOG 0–1 69 (81.2)
 ECOG 2–4 16 (18.8)
Tumor histology, No. (%)
 Adenocarcinoma 82 (96.5)
 Squamous cell carcinoma 3 (3.5)
Tumor stage, No. (%)
 IIIB 4 (4.7)
 IV 81 (95.3)
Symptomatic baseline brain metastases, No. (%)
 No 60 (70.6)
 Yes 25 (29.4)
  -Parenchymal metastases 16 (64.0)
  -Leptomeningeal metastases 7 (28.0)
  -Both parenchymal and leptomeningeal metastases 2 (8.0)
Abnormal organ function, No. (%)
 No 70 (82.4)
 Yes 15 (17.6)
  -Blood 5 (33.3)
  -Renal 9 (60.0)
  -Liver 2 (13.3)
EGFR mutation subtype, No. (%)
Exon 19 deletion 68 (80.0)
 Exon 21 L858R point mutation 11 (12.9)
 Rare or complex mutations 6 (7.1)
  -Exon 18 G719X 2 (33.1)
  -Exon 18 G719X and exon 20 S768I 1 (16.7)
  -Exon 18 G719X and exon 20 T790 M 1 (16.7)
  -Exon 19 deletion and exon 20 insertion 1 (16.7)
  -Exon 20 insertion 1 (16.7)
  1. Abbreviations: ECOG Eastern Cooperative Oncology Group, EGFR epidermal growth factor receptor